BioCentury
ARTICLE | Company News

Indivior divests Suboxone tablets to China’s Zhejiang Pukang

February 15, 2019 7:47 PM UTC

Indivior plc (LSE:INDV) will sell Chinese rights to its sublingual tablet formulation of Suboxone buprenorphine/naloxone to Zhejiang Pukang Biotechnology Co. Ltd. (Hangzhou, China) so that Indivior can focus on long-term growth of its extended release injectable drug formulations.

Indivior may receive up to $122.5 million, including a $1.5 million signing payment plus $16 million upon meeting closing conditions including classification of the drug by Chinese regulators. The company is also eligible to receive up to $105 million in sales milestones and payments for technical assistance to Zhejiang Pukang...